Oncolytic Virus Immunotherapy

Global Oncolytic Virus Immunotherapy Market to Reach US$429.1 Million by 2030

The global market for Oncolytic Virus Immunotherapy estimated at US$156.8 Million in the year 2024, is expected to reach US$429.1 Million by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Herpes Simplex Virus, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$189.7 Million by the end of the analysis period. Growth in the Vaccinia Virus segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.7 Million While China is Forecast to Grow at 24.8% CAGR

The Oncolytic Virus Immunotherapy market in the U.S. is estimated at US$42.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$99.7 Million by the year 2030 trailing a CAGR of 24.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.5% and 16.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

Global Oncolytic Virus Immunotherapy Market – Key Trends & Drivers Summarized

Why Are Oncolytic Viruses Re-emerging as a Disruptive Modality in Cancer Immunotherapy?

Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming. These genetically engineered or naturally occurring viruses selectively infect and replicate in tumor cells, causing their destruction while releasing tumor-associated antigens that stimulate anti-cancer immune responses. Unlike traditional chemotherapy or radiation, oncolytic viruses act locally at the tumor site and systemically through immune activation, positioning them as versatile agents in both solid and hematologic malignancies.

Despite early setbacks in the 1990s, recent advances in molecular virology, gene editing, and immune-oncology have revitalized interest in this approach. The 2015 approval of T-VEC (talimogene laherparepvec) by the FDA for melanoma marked a watershed moment, validating the concept of oncolytic virus therapy in clinical practice. Since then, a surge of clinical trials targeting multiple cancer types—including glioblastoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer—has expanded the scope and credibility of the modality. As monotherapies and in combination with checkpoint inhibitors, oncolytic viruses are becoming a cornerstone of next-generation immunotherapy regimens.

How Are Genetic Engineering and Combination Protocols Expanding the Potential of Oncolytic Virotherapy?

Recent breakthroughs in synthetic biology and vector engineering are significantly enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses. New viral constructs—based on herpes simplex virus (HSV), adenovirus, vaccinia virus, and reovirus—are being armed with immune-boosting transgenes such as GM-CSF, interleukins, or checkpoint blockade peptides. These modifications allow the virus to not only destroy tumor cells but also convert the tumor microenvironment (TME) into an immunologically active site.

Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.

Which Tumor Types and Geographies Are Shaping the Clinical and Commercial Landscape for Oncolytic Viruses?

Solid tumors with immunosuppressive microenvironments—such as melanoma, glioblastoma, pancreatic cancer, and hepatocellular carcinoma—are prime candidates for oncolytic virotherapy. These cancers typically respond poorly to conventional therapies and often lack T-cell infiltration, which oncolytic viruses can help overcome. Hematologic malignancies like lymphoma and multiple myeloma are also being targeted through engineered viruses capable of engaging both innate and adaptive immunity.

North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.

What Is Powering Long-Term Growth and Scientific Innovation in the Oncolytic Virus Immunotherapy Market?

The growth in the oncolytic virus immunotherapy market is powered by a paradigm shift toward immune-driven cancer control, rising incidence of refractory tumors, and growing regulatory openness to gene-modified biologicals. Oncolytic viruses offer a platform approach with customizable payloads and delivery options, making them highly adaptable to evolving immuno-oncology landscapes. Their ability to initiate cold-to-hot tumor conversion addresses one of the biggest challenges in cancer immunotherapy today.

Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virus Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types); Administration Route (Intratumoral Route, Intravenous Route); Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Amgen Inc.
• CG Oncology
• Creative Biolabs
• Daiichi Sankyo Co., Ltd.
• Genelux Corporation
• ImmVirX
• Imugene Limited
• Lokon Pharma AB
• Merck & Co., Inc.
• Oncolys BioPharma Inc.
• Oncolytics Biotech Inc.
• Oncorus Inc.
• Replimune Group Inc.
• SillaJen, Inc.
• Sorrento Therapeutics, Inc.
• Syneos Health, Inc.
• TILT Biotherapeutics Ltd.
• Transgene S.A.
• Viralytics Ltd.
• ViraTherapeutics GmbH

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.